TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Patients With Heart Failure With Preserved Ejection Fraction Adherence to ASV Therapy (PEP ASV)

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: SUPPORTIVE_CARE
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* 1. Patients 18 years or older 2. Patients with heart failure with preserved ejection fraction (HFpEF; LVEF ≥50%) 3. Hospital admission or equivalent (such as ER visit alone or clinic visit alone) and acute decompensated HF as determined by:~  1. Dyspnea at rest or with minimal exertion AND~ 2. Treatment with at least one dose of IV diuretic or ultrafiltration AND~ 3. At least two of the following signs and symptoms:~  i. Orthopnea ii. Pulmonary rales that do not clear with cough iii. Congestion on chest X-ray iv. Local BNP or NT pro-BNP level:~* No current AFib: BNP≥100 pg/mL or NT pro-BNP≥300 pg/mL OR~* Current AFib: BNP≥150 pg/mL or NT pro-BNP≥450 pg/mL 4. Sleep disordered breathing (SDB) documented by screening polygraphy with an AHI≥15 events/hour (e/hr) 5. Patient is able to fully understand study information and sign informed consent~Exclusion Criteria:~1. Right-sided heart failure without left-sided failure~2. Current chronic use (within 4 weeks of registry entry) of any PAP therapy (e.g., CPAP, APAP, or bi-level) or contraindicated for PAP therapy~3. Sustained systolic blood pressure \<80 mmHg at baseline~4. Complex congenital heart disease~5. Constrictive pericarditis~6. Chronic hypoxemia as evidenced by sustained oxygen saturation ≤ 85% at rest during the day or at start of nocturnal oximetry recording or regular use of oxygen therapy (day or night)~7. Transient ischemic attack (TIA) or Stroke within 3 months prior to registry entry~8. Definite clinically evident acute myocardial infarction within 3 months of registry entry~9. Known amyloidosis, hypertrophic obstructive cardiomyopathy, or arteriovenous fistulas~10. Moderate or greater valvular heart disease as the primary reason for heart failure~11. In the opinion of the investigator, the index acute decompensated HF event was not due primarily to uncontrolled AFib with fast ventricular response rate~12. Inability to comply with planned study procedures

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Active Patient Engagement (Type: EXPERIMENTAL): All patients are enrolled into the Active Patient Engagement (APE) arm. This arm will receive the APE intervention.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Evaluation of Lixisenatide Efficacy in Diabetes Mellitus Type 2 With Failure of Other GLP-1 Analog

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~Type Diabetes Mellitus on combination of basal insulin therapy and GLP1 analog, with secondary failure of non-fasting glycemic control~Exclusion Criteria:~* Pregnant or lactating woman~* Renal failure (eGFR\<30)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Lixisenatide (Type: EXPERIMENTAL): S.C. Lixisenatide 10 mcg for 2 weeks and then 10 mcg for 10 weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Silicone Arthroplasty vs. Arthrodesis in the Distal Interphalangeal Joint

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* primary osteoarthritis in the distal interphalangeal joint~* require surgical treatment~* patient aged 18 years and over~* signed written informed consent~Exclusion Criteria:~* posttraumatic osteoarthritis~* rheumatoid disease~* pregnant woman~* any disease process that would preclude accurate evaluation (e.g. neuromuscular, psychiatric or metabolic disorder)~* legal incompetence~* no knowledge of German

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- silicone arthroplasty (Type: EXPERIMENTAL): silicone arthroplasty
- arthrodesis (Type: ACTIVE_COMPARATOR): arthrodesis

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Aesthetic Outcome of Electrodesiccation and Curettage vs Excision With Complex Linear Closure

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: OTHER
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* 18 years of age or older~* Able to give informed consent themselves~* Patient scheduled for treatment of low risk cutaneous neoplasms on the trunk or extremities (superficial or nodular basal cell carcinoma and squamous cell carcinoma in-situ).~* Willing to return for follow up visit~Exclusion Criteria:~* Incarceration~* Under 18 years of age~* Pregnant Women~* Lesion size equal to or greater than 2 cm.~* Aggressive tumor subtypes(invasive squamous cell carcinoma (any subtype), infiltrative(sclerosing) basal cell carcinoma, micronodular basal cell carcinoma.~* Recurrent tumors

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- ED&C (Type: EXPERIMENTAL): The ED\&C arm will receive the standard ED\&C care.
- Excision (Type: EXPERIMENTAL): The excision arm will undergo standard excision with repair by complex linear closure.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Bispectral Index Monitoring During Testing in the Electrophysiology Lab

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: SUPPORTIVE_CARE
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* All patients who are having ICD placement and DFT testing will be invited to participate in this research study.~Exclusion Criteria:~* Patients who are not candidates for DFT testing, as is determined by the EP physician~* An example of such a patient would be one who is hemodynamically unstable;~* DFT testing is contraindicated in this case.

- Gender: ALL
- Minimum Age: 21 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- ICD testing BIS (Type: ACTIVE_COMPARATOR): Bispectral Index Monitoring will be used to assess adequacy of moderate sedation during DFT.
- ICD testing Ramsey (Type: ACTIVE_COMPARATOR): Ramsey Sedation Scale will be used to assess adequacy of moderate sedation during DFT

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Lipids Profile in Subclinical Hypothyroidism

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: CASE_ONLY
- Primary Purpose: None
- Time Perspective: CROSS_SECTIONAL
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Subjects with subclinical hypothyroidism~Exclusion Criteria:~* Patients taking L-thyroxin therapy~* Patients with known cardiovascular, cerebral or peripheral atherosclerotic disease.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 85 Years
- Healthy Volunteers: f

Study Arms:
- subclinical hypothyroidism (Type: None): Patients with subclinical hypothyroidism

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: The Effect of Intravenous Lidocaine on Post-extubation Laryngospasm

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* American Society of Anesthesia score are I or II~* Undergo for laparoscopic cholecystectomy~Exclusion Criteria:~* Patient's refusal~* History of upper respiratory tract infection (URTI) within 2 weeks~* Persistent type of hyper-reactive airway or asthma~* History of airway surgery~* History of gastro-esophageal reflex disease (GERD)~* Currently receiving sedating or analgesic medication~* Currently receiving the following medications:~  * Fluvoxamine~ * Erythromycin and Itraconazole~ * β -blocker or Cimetidine~* History of Lidocaine Allergy~* History of epilepsy disorder~* Pregnant or breastfeeding women~* History of Heavy Smoking ( a smoker with a daily cigarettes consumption of more than 20 pieces~* History of increased salivation by a disease or medication~* History of difficult intubation~* Two or more attempts of intubation

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 60 Years
- Healthy Volunteers: f

Study Arms:
- Lidocaine (Type: ACTIVE_COMPARATOR): Lidocaine 1% was prepared in 10 mL syringe= 10 mg/mL, dosage was 1mg/kg, one bolus or 10 mL/kg, with range of 2mg could be added or missed. The maximum dose is 100 mg for patients with weight of more than 100
- Placebo (Type: PLACEBO_COMPARATOR): Normal saline was prepared in 10 mL syringe, dosage was 1 mL/10 kg.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: safety issues
Please assess the completion status of the following clinical trial:

Trial Title: Incretin Physiology and Beta-cell Function Before and After Weight-loss

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: CASE_ONLY
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Caucasians without type 2 diabetes mellitus~* Normal OGTT (75 g of glucose) according to WHO's criteria~* Patients fulfilling the criteria for laparoscopic gastric banding~* Normal Hemoglobin~* Informed consent~Exclusion Criteria:~* Liver disease (ALAT \> 2 x normal level)~* Nephropathy (s-creatinin \> 130 µM or albuminuria)~* Relatives (parents/siblings) with T2DM~* Medical treatment witch cannot be stopped for 12 hours

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- A (Type: None): Obese patients without diabetes with a Body Mass Index \> 37 kg/m2

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Validation Study of Combined Positron Emission Tomography/Computer Tomography to Diagnose Infection and Inflammation

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: CASE_ONLY
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~Part project A~• Blood culture positive for staphylococcus aureus and unresolved origin of infection.~Part project B~* Fever of unknown origin~* Referred for FDG-PET/CT at the Department of Nuclear Medicine, Odense University Hospital.~Part project C~* Suspected vascular graft infection~* Referred for FDG-PET/CT at the Department of Nuclear Medicine, Odense University Hospital.~Exclusion Criteria:~* Patients incapable of giving, refusing or revoking consent~* Patients less than 18 years of age~* Patients from other regions than the Region of Southern Denmark~* Patients who cannot cooperate to PET/CT scan.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- FUO (Type: None): Patients with fever of unknown origin undergoing FDG-PET/CT as part of work-up.
- BUO (Type: None): Patients with bacteremia of unknown origin undergoing FDG-PET/CT as part of work-up.
- VGI (Type: None): Patients with vascular graft infections undergoing FDG-PET/CT as part of work-up.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Evaluation of The Vaginal Renewal™ Program in Gynecologic Cancer Patients Experiencing Sexual Dysfunction

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: SUPPORTIVE_CARE
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Age ≥18~* History of a gynecologic cancer~* No evidence of disease at time of inclusion in the study~* Postmenopausal (either surgical or natural menopause)~* Self report of sexual dysfunction that did not predate cancer diagnosis~* Suspected physical component to sexual dysfunction with the participant, not sexual partner~* Desire to improve sexual function~* ECOG Performance status score of 2 or better~* Six months or greater from last surgical and/or radiation treatment~Exclusion Criteria:~* History of sexual reassignment~* Presence of vaginal fistula~* Does not desire to improve sexual function~* Already using the vaginal renewal program~* Not fluent in English~* Incarceration

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Vaginal Renewal Program (Type: EXPERIMENTAL): None
- Standard of care (Type: ACTIVE_COMPARATOR): This will consist of still vaginal dilator and/or lubricant.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: MERIDIAN: A Study to Evaluate the Efficacy and Safety of Pegcetacoplan in Adults With Amyotrophic Lateral Sclerosis (ALS)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* At least 18 years of age~* Sporadic ALS diagnosed as definite, probable, or laboratory-supported probable as defined by the revised El Escorial criteria~* Slow vital capacity (SVC) ≥60% of the predicted value at screening~* Onset of ALS symptoms within 72 weeks (18 months) prior to screening~* Total ALSFRS-R score of ≥30 at screening~* Have vaccination within 5 years against Streptococcus pneumoniae, Neisseria meningitidis (types A, C, W, Y, and B), and Haemophilus influenzae (type B) or agree to receive vaccination~Exclusion Criteria:~* Confirmed or suspected other causes of neuromuscular weakness~* Diagnosed with another neurodegenerative disease (examples include Parkinson's disease and Huntington's disease)~* Significant pulmonary disorder not attributed to ALS (eg, chronic obstructive pulmonary disease, pulmonary fibrosis, cystic fibrosis, pulmonary arterial hypertension)~* If taking riluzole, participant must be on a stable dose for 30 days prior to the start of the screening period. Use of riluzole is not required for participation.~* If taking edaravone, participant must be on a stable dose for 60 days prior to the start of the screening period. Use of edaravone is not required for participation.~* Participation in any other investigational drug trial or exposure to other investigational agent, device, or procedure within 30 days or within 5-half lives of the treatment (whichever is longer) prior to the start of the screening period or during study participation~* Use of any other complement inhibitor within 30 days or within 5-half lives of the treatment (whichever is longer) prior to the start of the screening period or during study participation

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 1,080 mg pegcetacoplan (APL-2) (Type: EXPERIMENTAL): administered subcutaneously twice weekly
- Placebo administered subcutaneously twice weekly (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Spider Phobia Opposite Action Treatment Study

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* At Prescreen:~  * Total score of greater than or equal to 70 on the Fear of Spiders - Questionnaire (with higher scores indicating higher fear levels).~ * Indicates ongoing fear of spiders and inability to complete close approach towards spiders on brief questionnaire.~* At Screening visit: inability to complete close approach toward spiders as determined by the treatment context and generalization context Behavioral Approach Tests~Exclusion Criteria:~* Currently receiving psychotherapy for spider phobia

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: t

Study Arms:
- Biofeedback (Type: ACTIVE_COMPARATOR): Biofeedback Relaxation Training
- Standard Exposure (Type: ACTIVE_COMPARATOR): Exposure Therapy
- Exposure with Threat-Relevant OAs. (Type: EXPERIMENTAL): Exposure with Threat-Relevant Opposite Actions
- Exposure with Threat-Irrelevant OAs (Type: EXPERIMENTAL): Exposure with Threat-Irrelevant Opposite Actions

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility
Please assess the completion status of the following clinical trial:

Trial Title: Type of Material in Repair of Congenital Diaphragmatic Hernia

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Infants admitted to the neonatal intensive care unit with a diagnosis of congenital diaphragmatic hernia as proven by chest x-ray showing enteric contents in the thoracic cavity will be considered. Those who have birth weight equal to or over 2.2 kilograms and who are at or beyond 34 weeks gestation at the time of birth who survive until an operation can be performed will be considered. At operation, the patients with posterolateral diaphragmatic defects (Bockdalek Hernia) large enough to require placement of a patch to recreate the diaphragm will be included in the study.~Exclusion Criteria:~* Children diagnosed outside of the neonatal period will not be considered. Patients with the less common anteromedial or substernal defect (Morgagni Hernia) will not be included in the study as their physiology and rate of recurrence are incomparable to common posterolateral, Bockdalek Hernia.~Those patients under 2.2 kilograms and less than 34 weeks gestation have poor lung maturity to compound their inherent difficulty with pulmonary parenchymal hypoplasia and pulmonary vasculature hypertension making their chances of survival extremely low. Further compounding their dismal circumstance, they are not candidates for salvage extracorporeal membrane oxygenation (ECMO). Therefore, they will not be candidates for the study.~The rare case requiring repair of the hernia while on ECMO support will not be included due to the fact that this population has a very poor survival secondary to irreversible pulmonary hypertension. Further, the operation is performed while the patient is anticoagulated with heparin which is fraught with operative and post-operative bleeding.

- Gender: ALL
- Minimum Age: None
- Maximum Age: 2 Months
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Safety and Effectiveness of tPA in Intra-abdominal Abscesses

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2/PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Intrabdominal abscess~Exclusion Criteria:~* Hypersensitivity to tPA~* Recent stroke~* Uncontrolled htn~* Recent major hemorrhage~* Pregnancy

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Tissue Plasminogen Activator (Type: ACTIVE_COMPARATOR): tPA administered by drainage tube into abscess, allowed to dwell for one hour and then drained into drainage bag. Dose of tPA administered to be determined by the volume of drainage immediately post drain insertion. This intervention is done on day 0, 1 and 2.
- Instillation of Normal Saline (Type: SHAM_COMPARATOR): Insertion of abdominal drainage tube to drain intra-abdominal abscess. Normal Saline administered immediately post drain insertion. Normal Saline (10 cc) allowed to dwell for one hour, then allowed to drain into drainage bag.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Lumbar Disc Herniation Outcome Measures

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: CASE_CONTROL
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Must be at least 18 years of age and no older than 90 years of age~* Must have diagnosis of Lumbar disc herniation~* Must be able to understand English, and willing to consent to data collection~* Must be a current patient in our practice~Exclusion Criteria:~* Prisoner~* Unable to complete questionnaires

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 90 Years
- Healthy Volunteers: f

Study Arms:
- Surgical treatment for Lumbar disc herniation (Type: None): Patients who had or will have surgery for Lumbar disc herniation
- Non-surgical treatment for Lumbar disc herniation (Type: None): Patients that have chosen conservative treatment for lumbar disc herniation

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues